Huang X, et al. - Physicians designed this study to examine the changes of glucagon-like peptide-1 (GLP-1) and β-cell function after short-term continuous subcutaneous insulin infusion (CSII) treatment in newly diagnosed type 2 diabetes patients. Findings revealed that among these patients, short-term CSII treatment could obtain glycemic control target and recover β-cell function and GLP-1 secretion. This treatment possibly more effective in the overweight and middle-aged patients.